$8.44
2.31%
Nasdaq, Sep 25, 04:26 pm EDT. Closed.
ISIN
US45256X1037
Symbol
IBRX

ImmunityBio Inc Target price 2026 - Analyst rating & recommendation

ImmunityBio Inc Classifications & Recommendation

Buy
90%
Hold
10%

ImmunityBio Inc Price Target

Target Price $12.24
Price $8.44
Potential
Number of Estimates 6
6 Analysts have issued a price target ImmunityBio Inc 2027 . The average ImmunityBio Inc target price is $12.24. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 9 Analysts recommend ImmunityBio Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the ImmunityBio Inc stock has an average upside potential 2027 of . Most analysts recommend the ImmunityBio Inc stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Million $ 113.29 232.97
668.07% 105.64%
Net Margin -310.18% -438.07%
88.94% 41.23%

6 Analysts have issued a sales forecast ImmunityBio Inc 2026 . The average ImmunityBio Inc sales estimate is

$233m
unlock
. This is
40.52% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$264m 59.41%
unlock
, the lowest is
$207m 25.14%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $113m 668.07%
2026
$233m 105.64%
unlock
2027
$493m 111.53%
unlock
2028
$1.1b 124.84%
unlock
2029
$2.3b 111.01%
unlock
2030
$3.2b 35.97%
unlock
2031
$4.6b 44.39%
unlock
2032
$5.8b 26.36%
unlock
2033
$7.1b 22.34%
unlock

6 ImmunityBio Inc Analysts have issued a net profit forecast 2026. The average ImmunityBio Inc net profit estimate is

$-1.0b
unlock
. This is
2.84% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-1.0b 2.52%
unlock
, the lowest is
$-1.0b 4.01%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-351m 15.03%
2026
$-1.0b 190.43%
unlock
2027
$-140m 86.32%
unlock
2028
$403m 388.46%
unlock
2029
$1.0b 153.33%
unlock
2030
$1.5b 48.42%
unlock
2031
$2.4b 57.45%
unlock
2032
$3.1b 30.18%
unlock
2033
$3.8b 23.88%
unlock

Net Margin

2025 -310.18% 88.94%
2026
-438.07% 41.23%
unlock
2027
-28.34% 93.53%
unlock
2028
36.36% 228.30%
unlock
2029
43.65% 20.05%
unlock
2030
47.65% 9.16%
unlock
2031
51.96% 9.05%
unlock
2032
53.53% 3.02%
unlock
2033
54.20% 1.25%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ -0.38 -0.97
35.59% 155.26%
P/E negative
EV/Sales 41.97

6 Analysts have issued a ImmunityBio Inc forecast for earnings per share. The average ImmunityBio Inc EPS is

$-0.97
unlock
. This is
3.19% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-0.97 3.19%
unlock
, the lowest is
$-0.98 4.26%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-0.38 35.59%
2026
$-0.97 155.26%
unlock
2027
$-0.13 86.60%
unlock
2028
$0.38 392.31%
unlock
2029
$0.97 155.26%
unlock
2030
$1.44 48.45%
unlock
2031
$2.26 56.94%
unlock
2032
$2.95 30.53%
unlock
2033
$3.65 23.73%
unlock

P/E ratio

Current -8.98 34.85%
2026
-8.71 2.99%
unlock
2027
-63.65 630.77%
unlock
2028
22.07 134.67%
unlock
2029
8.71 60.53%
unlock
2030
5.87 32.61%
unlock
2031
3.73 36.46%
unlock
2032
2.86 23.32%
unlock
2033
2.31 19.23%
unlock

Based on analysts' sales estimates for 2026, the ImmunityBio Inc stock is valued at an EV/Sales of

41.97
unlock
and an P/S ratio of
38.40
unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 58.97 3.46%
2026
41.97 28.83%
unlock
2027
19.84 52.72%
unlock
2028
8.82 55.52%
unlock
2029
4.18 52.61%
unlock
2030
3.08 26.46%
unlock
2031
2.13 30.74%
unlock
2032
1.69 20.86%
unlock
2033
1.38 18.27%
unlock

P/S ratio

Current 53.95 18.34%
2026
38.40 28.84%
unlock
2027
18.15 52.72%
unlock
2028
8.07 55.52%
unlock
2029
3.83 52.61%
unlock
2030
2.81 26.45%
unlock
2031
1.95 30.74%
unlock
2032
1.54 20.86%
unlock
2033
1.26 18.26%
unlock

Current ImmunityBio Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
➜
Locked
Locked Jun 02 2026
BTIG
Locked
➜
Locked
Locked May 21 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked May 20 2026
D. Boral Capital
Locked
➜
Locked
Locked May 05 2026
D. Boral Capital
Locked
➜
Locked
Locked Apr 21 2026
D. Boral Capital
Locked
➜
Locked
Locked Apr 08 2026
D. Boral Capital
Locked
➜
Locked
Locked Mar 26 2026
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Jun 02 2026
Locked
BTIG:
Locked
➜
Locked
May 21 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
May 20 2026
Locked
D. Boral Capital:
Locked
➜
Locked
May 05 2026
Locked
D. Boral Capital:
Locked
➜
Locked
Apr 21 2026
Locked
D. Boral Capital:
Locked
➜
Locked
Apr 08 2026
Locked
D. Boral Capital:
Locked
➜
Locked
Mar 26 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today